Patient Empowerment Program: A Rare Disease Podcast
n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
Latest episode
106 episodes
- The Vrtochnick family recalls the moment they were told that their son’s investigational new drug application (IND) received a “may proceed” authorization from the FDA, meaning that a green light has been signaled for Gunnar to receive his ASO medicine charitably created by n-Lorem. Gunnar, a pre-teen from Wisconsin, lives with KIF1A-Associated Neurological Disorder (KAND) which causes him difficulties with spasticity and motor function. With this authorization, he hopes to begin treatment in the coming months.
Hear about Gunnar's diagnosis, what a treatment means for his family, the community impact of the colloquium, and more in this Patient Empowerment Program podcast episode.
In this episode we discuss:
1:30 - Involvement in Rescue 7 and it becoming a colloquium staple for families
2:35 – Meet the Vrtochnick family
3:00 – Community impact of the Colloquium and meeting others facing similar difficulties
4:07 – Gunnar's symptoms and diagnosis
5:30 – What an n-Lorem discovered, developed, and charitably provided ASO medicine means to their family
7:48 – The moment they were told that their son's IND received a "May proceed" authorization from the FDA
11:43 – Gunnar's interests and him learning the importance of giving back
---
Links:
2027 Colloquium Interest Form
2026 Colloquium Recap
Donate to n-Lorem
Sponsors:
ChemGenes
GondolaBio - We're addressing perhaps the most difficult decision n-Lorem has to make in our work, declining a patient application. Today, our acceptance rate is ~59%. These decisions are made with heavy hearts at n-Lorem, and we are aware of how heartbreaking the decision to decline an application may be for a patient and their family. In this episode, we'll discuss the main reasons a patient's application may be denied, including safety, geography, and other factors.
On This Episode We Discuss:
1:43 – Non-technical issues: Outside of USA, inability to find treating physician, patient population size, if the patient is being treated by another experimental medicine, including repurposed drugs
7:15 – Definitions to better understand the conversation: Heterozygous mutation, haploinsufficiency
9:40 – n-Lorem must understand the cause of the disease, the nature of the mutation, and n-Lorem must be confident that the ASO designed would deliver value to the patient
12:35 – n-Lorem must be confident that only a single gene is causing phenotypes, and that the target is not a null mutation
13:37 – n-Lorem may accept patients, but then discontinue a program if the patient cells are unable to be grown for lab use and testing
14:56 – For patients requiring an allele-selective ASO, n-Lorem must identify non-pathogenic mutations to attempt to create an ASO capable of helping the patient
Links:
Donate - https://www.nlorem.org/donate/
Sponsors:
Hongene - https://www.hongene.com/
GondolaBio - https://gondolabio.com/ - A lot can happen in a year, and at n-Lorem, this past year has brought important milestones, new developments, and plenty to discuss at the upcoming 2026 Nano-rare Patient Colloquium.
In this special Colloquium preview episode, Brady Huggett, editor-in-chief of Asimov Press and longtime moderator of the Colloquium’s patient experience panel, returns to sit down with n-Lorem CEO Stan Crooke. Together, they reflect on the past year, explore some of the topics likely to take center stage, and preview what attendees can expect at the 2026 Nano-rare Patient Colloquium.
On this episode:
2:28 – What is a day in the life of an n-Lorem research team member?
9:08 – How many ASOs are required to move into tolerability studies and what may cause a program to be terminated
12:05 – Improvements in efficiencies, bringing down costs, and growth have allowed n-Lorem to respond to the extraordinary demand
13:14 – Discussing the creation of individualized ASOs for two boys with SCN2A mutations and their potential to help others with the same mutation and single nucleotide variant
25:00 – Thoughts on the FDA’s Plausible Mechanism Framework
29:00 – Commercial opportunities will not alter the n-Lorem charitable arm but will provide sustainable revenues to charitably treat more patients
36:05 – What are the Limits of Hope and expanding those limits
37:54 – Empathy is an expanded sense of self, and a sphere of oneness is felt at the Colloquium
Links:
2026 Nano-rare Patient Colloquium
Donate to n-Lorem
Episode and NRPC Gold Sponsors:
ChemGenes
GondolaBio
Hongene Biotech Realities of the Nano-rare: Siblings, Unfairness and Hard Truths with Sally Jackson
26/08/2026 | 1h 19 mins.Sally Jackson is a former actress, cookbook co-author, and mother of Susannah. In this Realities of the Nano-rare episode, Sally lets us into her family’s bubble, speaking candidly about the deeply complex and often terrifying realities of navigating KIF1A-associated neurological disorder. From helping Susannah's sibling understand the harsh consequences of her disease to confronting distress, uncertainty, and the profound unfairness of it all, Sally shares the difficult truths her family has faced and continues to carry and fight through.
On this episode:
4:00 – Sally and her husband's story first began in a college acting class
9:55 – Forming a career alongside celebrity chef Bobby Flay
13:30 – Family of four including Nat and Susannah
16:55 – Early abnormalities and a diagnosis initially withheld from the family
22:50 – The fight for Susannah and others with KIF1A post-diagnosis
29:24 – Dealing with the seriousness of a degenerative condition while trying to live a normal life
34:00 – Enduring relentless seizures
38:31 – The reality that not even doctors know what's best and often experiment to attempt to relieve rare disease symptoms, and the unfairness of rare disease
45:00 – Informing siblings about the severity and consequences of rare disease
57:00 – Changing the course of their life to advocate to the fullest extent
1:02:25 – After the long fight, there was an ASO
1:07:30 – After years of treatment, Susannah had to stop, a crushing blow that was followed by worsening symptoms before once again resuming treatments
Links:
Nano-rare Patient Colloquium 2026
Support n-Lorem with a donation
Today's Sponsor - Hongene- Silence ALS is an initiative that brings together Columbia University and n-Lorem to support the discovery, development, and treatment of individuals living with nano-rare genetic forms of amyotrophic lateral sclerosis (ALS) through personalized antisense oligonucleotide (ASO) medicines. Learn more about this initiative and one of its co-founders, leading ALS physician-scientist Dr. Neil Shneider in this episode of the Patient Empowerment Program podcast.
On this episode we discuss:
4:00 – Developing tools to discuss with patients about the real and scary outcomes of ALS, and changing the course of a neurogenerative and fatal disease
6:52 – Experimental ASO treatments for genetic forms of ALS
9:30 – The creation of Silence ALS to treat extremely rare forms of genetically caused ALS like CHCHD10 and TARDBP and moving the collaboration forward
12:36 – Serving present day and future patient populations with the Silence ALS initiative
17:30 – Learnings gained from treated nano-rare ALS patients may translate to broader ALS groups
22:33 – To ALS patients and families, hope is powerful and makes a difference
Links:
Donate - https://www.nlorem.org/donate/
NRCP26 - https://www.nlorem.org/nano-rare-patient-colloquium-2026/
Hongene - https://www.hongene.com/
More Education podcasts
Trending Education podcasts
About Patient Empowerment Program: A Rare Disease Podcast
Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.
Podcast websiteListen to Patient Empowerment Program: A Rare Disease Podcast, Begin Again with Davina McCall and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features








































